MX2023008056A - Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo. - Google Patents

Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.

Info

Publication number
MX2023008056A
MX2023008056A MX2023008056A MX2023008056A MX2023008056A MX 2023008056 A MX2023008056 A MX 2023008056A MX 2023008056 A MX2023008056 A MX 2023008056A MX 2023008056 A MX2023008056 A MX 2023008056A MX 2023008056 A MX2023008056 A MX 2023008056A
Authority
MX
Mexico
Prior art keywords
compounds
cereblon
same
bifunctional compounds
binds
Prior art date
Application number
MX2023008056A
Other languages
English (en)
Inventor
Yimin Qian
Andrew P Crew
Keith R Hornberger
Michael Berlin
Jing Wang
Hanqing Dong
Lawrence B Snyder
Kurt Zimmermann
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62977181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023008056(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of MX2023008056A publication Critical patent/MX2023008056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

La descripción se refiere a los compuestos de unión a la ligasa E3 cereblon, que incluye los compuestos bifuncionales que los comprenden, que encuentran utilidad como moduladores de la ubiquitinación dirigida, especialmente inhibidores de una variedad de polipéptidos y otras proteínas que se degradan y/o se inhiben de cualquier otra manera por los compuestos bifuncionales de conformidad con la presente descripción. En particular, la descripción proporciona compuestos, que contienen en un extremo un ligando que se une a la ligasa de ubiquitina E3 cereblon y en el otro extremo una porción que se une a una proteína diana de manera que la proteína diana se coloca en proximidad a la ligasa de ubiquitina para efectuar la degradación (e inhibición) de esa proteína. Pueden sintetizarse compuestos que exhiban una amplia gama de actividades farmacológicas consistentes con la degradación/inhibición de polipéptidos seleccionados de casi cualquier tipo.
MX2023008056A 2017-01-31 2019-07-30 Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo. MX2023008056A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762452972P 2017-01-31 2017-01-31

Publications (1)

Publication Number Publication Date
MX2023008056A true MX2023008056A (es) 2023-09-12

Family

ID=62977181

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009046A MX2019009046A (es) 2017-01-31 2018-01-31 Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
MX2023008056A MX2023008056A (es) 2017-01-31 2019-07-30 Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019009046A MX2019009046A (es) 2017-01-31 2018-01-31 Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.

Country Status (12)

Country Link
US (2) US20180215731A1 (es)
EP (1) EP3577109A4 (es)
JP (2) JP2020506922A (es)
KR (1) KR20190116315A (es)
CN (2) CN115974840A (es)
AU (3) AU2018215212B2 (es)
BR (1) BR112019015484A2 (es)
CA (1) CA3050309A1 (es)
CO (1) CO2019009424A2 (es)
IL (2) IL312367A (es)
MX (2) MX2019009046A (es)
WO (1) WO2018144649A1 (es)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
AU2017367872B2 (en) * 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
KR102173464B1 (ko) 2016-12-01 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
WO2018119448A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018119441A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
MX2019008934A (es) 2017-01-26 2019-11-05 Arvinas Operations Inc Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
KR102014478B1 (ko) * 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
AU2018301335B2 (en) 2017-07-10 2022-09-15 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
IL275649B2 (en) 2017-12-26 2023-12-01 Kymera Therapeutics Inc IRAK joints and used in them
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
MX2020010368A (es) 2018-04-01 2021-01-08 Arvinas Operations Inc Compuestos dirigidos a brm y métodos de uso asociados.
MX2020010420A (es) 2018-04-04 2020-12-11 Arvinas Operations Inc Moduladores de la proteólisis y métodos asociados de uso.
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
SI3784663T1 (sl) 2018-04-23 2023-11-30 Celgene Corporation Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
AU2019294836B2 (en) * 2018-06-29 2024-06-20 Dana-Farber Cancer Institute, Inc. Bispecific degraders
AU2019293235A1 (en) * 2018-06-29 2020-12-17 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
ES2963694T3 (es) 2018-07-10 2024-04-01 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2)
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
CN108774215A (zh) * 2018-08-15 2018-11-09 翟学旭 含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP3846800A4 (en) 2018-09-04 2022-08-24 C4 Therapeutics, Inc. COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1
US11319330B2 (en) * 2018-09-07 2022-05-03 Medshine Discovery Inc. Tricyclic furan-substituted piperidinedione compound
CN113423427A (zh) * 2018-11-30 2021-09-21 凯麦拉医疗公司 Irak降解剂和其用途
JP2022510313A (ja) * 2018-12-03 2022-01-26 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法
US11149007B2 (en) 2018-12-19 2021-10-19 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
EP3897635A4 (en) 2018-12-19 2022-08-31 Celgene Corporation SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF
WO2020132561A1 (en) * 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
US20220105188A1 (en) * 2019-02-07 2022-04-07 Korea Research Institute Of Chemical Technology Target protein eed degradation-inducing degraducer, preparation method thereof, and pharmaceutical composition for preventing or treating diseases related to eed, ezh2, or prc2, comprising same as active ingredient
US20220143183A1 (en) * 2019-02-23 2022-05-12 New York University Photoswitchable protacs and synthesis and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US20220241424A1 (en) 2019-04-16 2022-08-04 Northwestern University Treatment of cancer
WO2020211822A1 (zh) * 2019-04-18 2020-10-22 成都海创药业有限公司 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
CN114423463A (zh) 2019-05-06 2022-04-29 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
WO2020251969A1 (en) * 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
US20210060008A1 (en) * 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN114641337A (zh) * 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
JP7209897B2 (ja) * 2019-09-12 2023-01-20 メッドシャイン ディスカバリー インコーポレイテッド Ｃｒｂｎタンパク質モジュレーターとしての二環式化合物
PE20221417A1 (es) * 2019-09-16 2022-09-20 Novartis Ag Degradadores bifuncionales de brd9 y sus metodos de uso
EP4031243A1 (en) * 2019-09-16 2022-07-27 Novartis AG Glue degraders and methods of use thereof
JP7502425B2 (ja) 2019-10-01 2024-06-18 アルヴィナス・オペレーションズ・インコーポレイテッド Ｂｒｍ標的化化合物および関連使用方法
US20220323457A1 (en) 2019-10-17 2022-10-13 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN110885332B (zh) * 2019-12-06 2022-03-18 中国人民解放军第二军医大学 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Iraq joints and their uses
US20230020607A1 (en) * 2019-12-17 2023-01-19 Orionis Biosciences, Inc. Modulation of protein degradation
BR112022012110A2 (pt) * 2019-12-19 2022-12-13 Arvinas Operations Inc Compostos e métodos para a degradação direcionada de receptor androgênico
KR20220119415A (ko) 2019-12-20 2022-08-29 씨4 테라퓨틱스, 인코포레이티드 Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
EP4090371A4 (en) * 2020-01-14 2024-04-03 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES
WO2021143816A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2021143822A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 并环酰亚胺类衍生物、其制备方法及其在医药上的应用
PE20231067A1 (es) 2020-02-14 2023-07-17 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
EP3875456A1 (en) * 2020-03-02 2021-09-08 Technische Universität Darmstadt Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
CN111249276B (zh) * 2020-03-05 2021-07-13 南京巴傲得生物科技有限公司 吲哚布洛芬制备cbp溴区抑制试剂的用途
CN115279370A (zh) 2020-03-05 2022-11-01 C4医药公司 用于brd9的靶向降解的化合物
CN115052874A (zh) * 2020-03-06 2022-09-13 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物的结晶及其制备方法
CN113387931A (zh) * 2020-03-13 2021-09-14 四川海思科制药有限公司 一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc. PROTEOLYSIS REGULATOR AND METHOD OF USE
US20230133538A1 (en) * 2020-03-18 2023-05-04 Dana-Farber Cancer Institute, Inc. Targeted degraders of aberrant tau based on the pet tracer pbb3
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
EP3911654A4 (en) * 2020-03-27 2022-05-11 Uppthera COMPOUND INDUCING SELECTIVE DEGRADATION OF PLK1
WO2021210878A1 (ko) * 2020-04-17 2021-10-21 광주과학기술원 Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
CN113563414B (zh) * 2020-04-29 2022-08-12 泰比棣医药科技(石家庄)有限公司 一种组织靶向的蛋白靶向降解化合物及其用途
CN113582974B (zh) * 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
US20230357249A1 (en) * 2020-05-14 2023-11-09 The Regents Of The University Of Michigan Androgen receptor protein degraders with a tricyclic cereblon ligand
US20230192644A1 (en) * 2020-05-21 2023-06-22 Dana-Farber Cancer Institute, Inc. Piperidine-2,6-diones as small molecule degraders of helios and methods of use
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
JP2023531390A (ja) * 2020-06-12 2023-07-24 シャンハイ ジェミンケア ファーマシューティカルズ カンパニー、リミテッド フタラジノン化合物、並びにその調製方法及びその医薬用途
KR102559329B1 (ko) * 2020-07-02 2023-07-25 포항공과대학교 산학협력단 신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
US20230357193A1 (en) * 2020-07-09 2023-11-09 Sichuan Haisco Pharmaceutical Co., Ltd. Compound capable of inhibiting and degrading androgen receptors, and pharmaceutical compositions and pharmaceutical uses thereof
EP4186904A1 (en) * 2020-07-21 2023-05-31 Ubix Therapeutics, Inc. Compound for androgen receptor degradation, and pharmaceutical use thereof
KR20220014952A (ko) * 2020-07-29 2022-02-08 한국화학연구원 안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
MX2023001401A (es) * 2020-08-03 2023-05-03 Captor Therapeutics S A Degradadores de proteinas de bajo peso molecular y sus aplicaciones.
KR20230050375A (ko) * 2020-08-05 2023-04-14 상하이 리딩택 파마슈티컬 코., 엘티디. 단백질 표적화 및 분해용 화합물, 이의 제조방법 및 용도
WO2022048605A1 (zh) * 2020-09-04 2022-03-10 南昌奥瑞药业有限公司 一种杂环化合物、其制备方法、中间体、组合物以及应用
CN114163444B (zh) * 2020-09-11 2023-07-14 江苏恒瑞医药股份有限公司 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
CN114181277A (zh) * 2020-09-15 2022-03-15 江苏恒瑞医药股份有限公司 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
CR20230185A (es) 2020-09-30 2023-06-27 Astrazeneca Ab Compuestos y su uso en el tratamiento del cáncer
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
EP4289841A1 (en) * 2021-02-04 2023-12-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
WO2022178532A1 (en) * 2021-02-19 2022-08-25 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2022195355A1 (en) * 2021-03-15 2022-09-22 Novartis Ag Benzisoxazole derivatives and uses thereof
TW202304928A (zh) 2021-03-23 2023-02-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
WO2022206737A1 (zh) * 2021-03-29 2022-10-06 江苏恒瑞医药股份有限公司 四氢萘类化合物、其制备方法及其在医药上的应用
CN115141179A (zh) * 2021-03-31 2022-10-04 江苏恒瑞医药股份有限公司 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
CN117279910A (zh) 2021-04-16 2023-12-22 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
CN113603676B (zh) * 2021-04-28 2022-05-24 浙江工业大学 基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
IL308104A (en) * 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
CA3217417A1 (en) 2021-05-05 2022-11-10 Kevin M. Guckian Compounds for targeting degradation of bruton's tyrosine kinase
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022250350A1 (ko) * 2021-05-26 2022-12-01 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
KR102474999B1 (ko) * 2021-05-26 2022-12-07 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
KR102489160B1 (ko) * 2021-05-26 2023-01-18 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
CN116323619A (zh) * 2021-05-26 2023-06-23 因诺库尔治疗公司 哌啶二酮衍生物
WO2022255888A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2022255889A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255890A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
EP4366834A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
KR20240035526A (ko) 2021-07-07 2024-03-15 바이오젠 엠에이 인코포레이티드 Irak4 단백질의 분해를 표적하는 화합물
EP4367112A1 (en) 2021-07-09 2024-05-15 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
WO2023016518A1 (zh) * 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
CN117813307A (zh) 2021-08-18 2024-04-02 新锐思生物制药股份有限公司 白介素-1受体相关激酶的双官能降解物及其治疗用途
WO2023025159A1 (zh) * 2021-08-23 2023-03-02 上海领泰生物医药科技有限公司 Irak4降解剂及其制备方法和应用
WO2023034411A1 (en) 2021-09-01 2023-03-09 Oerth Bio Llc Compositions and methods for targeted degradation of proteins in a plant cell
WO2023056443A1 (en) * 2021-10-01 2023-04-06 Dana-Farber Cancer Institute, Inc. Binders of cereblon and methods of use thereof
WO2023059792A1 (en) * 2021-10-06 2023-04-13 C4 Thrapeutics, Inc. Coronavirus non-structural protein 3 degrading compounds
WO2023066350A1 (zh) * 2021-10-22 2023-04-27 标新生物医药科技(上海)有限公司 Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
CN118139858A (zh) 2021-10-28 2024-06-04 吉利德科学公司 吡地嗪-3(2h)-酮衍生物
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023081224A1 (en) * 2021-11-03 2023-05-11 St. Jude Children's Research Hospital, Inc. Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
WO2023081452A1 (en) * 2021-11-05 2023-05-11 University Of South Carolina Small-molecule degraders of cdk8 and cdk19
WO2023096987A1 (en) 2021-11-24 2023-06-01 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2023097031A1 (en) 2021-11-24 2023-06-01 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN114085213B (zh) * 2022-01-20 2022-03-25 苏州国匡医药科技有限公司 一种arv-471的制备方法
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
WO2023180388A1 (en) * 2022-03-24 2023-09-28 Glaxosmithkline Intellectual Property Development Limited 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023212599A2 (en) * 2022-04-26 2023-11-02 Endotarget Inc. Compounds and methods for targeted degradation of estrogen receptors
US20240018149A1 (en) * 2022-06-30 2024-01-18 Chu-Chiang Chen Protein degradation compounds and methods of use
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015412A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
CN115089588A (zh) * 2022-08-22 2022-09-23 云南大学 达沙布韦作为e3连接酶新型配体构建protac的应用
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024054953A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024054955A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024054954A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024051766A1 (zh) * 2022-09-08 2024-03-14 标新生物医药科技(上海)有限公司 基于cereblon蛋白设计的分子胶化合物及其应用
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
WO2024056005A1 (zh) * 2022-09-14 2024-03-21 先声再明医药有限公司 多并环类化合物及其用途
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024073475A1 (en) * 2022-09-27 2024-04-04 Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. Cereblon ligands and uses thereof
WO2024067793A1 (zh) * 2022-09-29 2024-04-04 海南先声再明医药股份有限公司 一类稠环化合物及其用途
WO2024067781A1 (zh) * 2022-09-29 2024-04-04 江苏恒瑞医药股份有限公司 一种四氢萘类衍生物的可药用盐、晶型及制备方法
CN117801051A (zh) * 2022-09-30 2024-04-02 苏州德亘生物医药有限公司 一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
WO2024091975A1 (en) 2022-10-24 2024-05-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20240075764A (ko) * 2022-11-22 2024-05-29 주식회사 이노큐어테라퓨틱스 cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
WO2024112120A1 (ko) * 2022-11-22 2024-05-30 주식회사 이노큐어테라퓨틱스 신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물
WO2024112122A1 (ko) * 2022-11-22 2024-05-30 주식회사 이노큐어테라퓨틱스 Brd 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
WO2024121256A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012084A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
ATE458485T1 (de) * 2003-07-11 2010-03-15 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
WO2008087643A2 (en) * 2007-01-16 2008-07-24 Proteologics Ltd Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
JP2012532929A (ja) * 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
KR102668696B1 (ko) * 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US20150291562A1 (en) * 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US10071164B2 (en) * 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3256470B1 (en) * 2014-12-23 2023-07-26 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3247708A4 (en) * 2015-01-20 2018-09-12 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
HUE054149T2 (hu) * 2015-06-04 2021-08-30 Arvinas Operations Inc Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR20180035828A (ko) * 2015-07-10 2018-04-06 아비나스 인코포레이티드 단백질 분해의 mdm2계 조절인자 및 관련된 이용 방법
AU2016294450A1 (en) * 2015-07-13 2017-12-07 Arvinas Operations, Inc. Alanine-based modulators of proteolysis and associated methods of use
BR112018008918A8 (pt) * 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
MX2018011216A (es) * 2016-03-16 2019-08-29 H Lee Moffitt Cancer Ct & Res Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Also Published As

Publication number Publication date
WO2018144649A8 (en) 2019-08-22
JP2024023277A (ja) 2024-02-21
CA3050309A1 (en) 2018-08-09
AU2022221386A1 (en) 2022-09-15
CN115974840A (zh) 2023-04-18
IL268069A (en) 2019-09-26
WO2018144649A1 (en) 2018-08-09
US20230183209A1 (en) 2023-06-15
EP3577109A1 (en) 2019-12-11
US20180215731A1 (en) 2018-08-02
CN110612294A (zh) 2019-12-24
AU2018215212A1 (en) 2019-07-11
AU2018215212B2 (en) 2022-06-02
IL312367A (en) 2024-06-01
AU2024203251A1 (en) 2024-06-06
MX2019009046A (es) 2019-10-30
EP3577109A4 (en) 2020-11-18
JP2020506922A (ja) 2020-03-05
KR20190116315A (ko) 2019-10-14
RU2019123462A (ru) 2021-01-27
RU2019123462A3 (es) 2021-05-24
CO2019009424A2 (es) 2020-02-28
BR112019015484A2 (pt) 2020-04-28
CN110612294B (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
MX2023008056A (es) Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
MX2023002134A (es) Ligandos de cereblon y compuestos bifuncionales que los comprenden.
MX2018000360A (es) Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
MX2018000471A (es) Moduladores de proteolisis basados en alanina y metodos de uso asociados.
MX2017015605A (es) Moduladores de proteolisis basados en imida y metodos de uso asociados.
MX2021012926A (es) Moduladores de la proteolisis basados en imida y metodos de uso asociados.
MX2021010482A (es) Compuestos y metodos para la degradacion mejorada de proteinas especificas.
MX2022009478A (es) Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
WO2018119441A8 (en) Egfr proteolysis targeting chimeric molecules and associated methods of use
PH12020500663A1 (en) Brm targeting compounds and associated methods of use
MX2022014690A (es) Protac dirigidos a la proteina tau y metodos asociados de uso.
MX2023004018A (es) Moduladores de la proteolisis del receptor de estrogeno y metodos asociados de uso.
WO2019195609A3 (en) Modulators of proteolysis and associated methods of use
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
MX2019007649A (es) Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
BR112018068702A2 (pt) inibidores bicíclicos em ponte de menin-mll e métodos de uso
MX2022006089A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
EP3617235A4 (en) ASSOCIATION WITH A SUBSTANCE WITH AFFINITY TO SOLUBLE PROTEIN, FITTABLE PART AND REACTIVE GROUP OR SALT THEREOF
MX2022010583A (es) Derivados de tetrahidronaftaleno y tetrahidroisoquinolina como degradores del receptor de estrogeno.
AU2018382122A1 (en) ALK protein degradation agent and anti-tumor application thereof
TN2018000044A1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
MY199019A (en) Pd-1 antibodies
ZA201504081B (en) Engineering and optimization of improved systems ,methods and enzyme compositions for sequence manipulation
WO2012174489A3 (en) Small molecule composite surfaces as inhibitors of protein-protein interactions
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof